Literature DB >> 11571732

The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma.

M Yaron1, T Levy, A Chetrit, H Levavi, G Sabah, D Schneider, R Halperin, Z Ben-Rafael, E Friedman.   

Abstract

BACKGROUND: Endometrial carcinoma is considered a hormonal-dependent tumor; estrogen induces endometrial cellular proliferation, whereas progestins display an antiproliferative effect on endometrial tissue. The role that androgen and its receptor (androgen receptor [AR]) play in the pathogenesis of endometrial carcinoma is less clear. Although androgen has an in vitro inhibitory effect on endometrial cell proliferation, up to 75% of endometrial carcinoma express AR somatically. A polymorphic CAG repeat within exon 1 of the AR encodes for a polyglutamine tract, with length range of 8 to 33 repeats, which is inversely correlated with the transcriptional activity of the AR.
METHODS: To gain insight into the role of AR in endometrial carcinoma, the authors analyzed the polymorphic CAG repeat in 79 Jewish Israeli patients with endometrial carcinoma as compared with 44 healthy Jewish women serving as controls. Analysis was conducted using germline DNA as template and using polymerase chain reaction primers flanking the CAG repeat with subsequent fluorescent determination of allele sizes.
RESULTS: Allele size range of the longer of the two alleles in the patients was 11-33 (mean, 19.8 +/- 2.7) and in the controls 10-22 (mean, 17.9 +/- 1.9), a statistically significant difference (P < 0.01). Allele size variation within the patient group did not correlate with disease stage, grade, reproductive history, or age at diagnosis.
CONCLUSIONS: The authors conclude that AR-CAG repeat length differs in Jewish patients with endometrial carcinoma as compared with healthy individuals in Israel, and this finding increases the possibility that the AR is involved in the predisposition to this neoplasm. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571732     DOI: 10.1002/1097-0142(20010901)92:5<1190::aid-cncr1437>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  The Jerusalem Perinatal Study cohort, 1964-2005: methods and a review of the main results.

Authors:  Susan Harlap; A Michael Davies; Lisa Deutsch; Ronit Calderon-Margalit; Orly Manor; Ora Paltiel; Efrat Tiram; Rivka Yanetz; Mary C Perrin; Mary B Terry; Dolores Malaspina; Yechiel Friedlander
Journal:  Paediatr Perinat Epidemiol       Date:  2007-05       Impact factor: 3.980

2.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 3.  Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms.

Authors:  J L Illuzzi; D M Wilson
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

5.  Genetic variation in the androgen receptor gene and endometrial cancer risk.

Authors:  Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Louise A Brinton; Jolanta Lissowska; Beta Peplonska; Stephen Chanock; Mia M Gaudet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

6.  Short androgen receptor poly-glutamine-promoted endometrial cancer is associated with benzo[a]pyrene-mediated aryl hydrocarbon receptor activation.

Authors:  Lumin Chen; Bo-Ying Bao; Wei-Chun Chang; Jason Yen-Ping Ho; Bi-Hua Cheng; Chung-Lin Wang; Qifeng Tang; Wei-Chung Cheng; Hui-Wen Chang; Yao-Ching Hung; Wen-Lung Ma
Journal:  J Cell Mol Med       Date:  2017-08-07       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.